Product Name & Packaging
Brand Name: MT2 TANNING NASAL
Generic Name: Melanotan II
Strength & Packaging: 10 mg/10 mL nasal preparation, Strawberry/Watermelon flavor. Public medical literature refers to “MT2” as melanotan II, a synthetic melanocortin analogue.

Description
Melanotan II is a synthetic melanocortin receptor agonist associated with increased skin pigmentation through melanocortin pathway activity. However, it is widely described in the medical literature as an unapproved/investigational substance rather than an established licensed medicine, so product quality, formulation, and labeling may vary significantly.

Indications
At present, I could not verify any approved therapeutic indication for melanotan II from authoritative regulatory sources. It has been discussed publicly in connection with cosmetic tanning, but formal approved medical indications are not established in the sources reviewed.

Dosage & Administration
Because melanotan II is not an established approved medicine, I could not verify a standard, regulator-approved dosing regimen for a nasal 10 mg/10 mL product. Any presentation, route of administration, or strength should therefore be confirmed directly from the manufacturer’s documentation and applicable local regulatory requirements before inclusion in a formal pharmacy catalog.

Mechanism of Action
Melanotan II acts as a non-selective melanocortin receptor agonist. Literature describes activity at melanocortin pathways involved in pigmentation, with MC1 receptor-related effects contributing to increased melanin production and skin darkening.

Precautions
Because melanotan II is not an approved standard pharmaceutical product, its safety profile is not fully established. Published reports and reviews note concerns including variable product quality and potential systemic effects beyond pigmentation. Caution is warranted in any individual with cardiovascular, renal, dermatologic, or other underlying medical risk factors.

Side Effects
Reported and discussed adverse effects in the literature include unintended systemic effects, and case reports have linked melanotan II exposure to serious events such as priapism and possible renal injury in isolated cases. Because these products are not standardized approved medicines, the full adverse-effect profile remains uncertain.

Storage
Storage conditions should follow the manufacturer’s specific label and handling instructions. I could not verify a standardized approved storage monograph for this nasal melanotan II product from authoritative drug-label sources.